ASH 2020 | allo-SCT improves survival following venetoclax and azacitidine therapy in AML
Daniel Pollyea, MD, MS, University of Colorado School of Medicine, Denver, CO, presents interim data from a study that evaluated the clinical benefit of undergoing allogeneic stem cell transplants (allo-SCT) following initial venetoclax (ven) and azacitidine (aza) therapy in patients with acute myeloid leukemia (AML). Patients who had received initial ven-aza therapy were identified and outcomes were compared between patients who received allo-SCT and those who did not, either due to ineligibility or personal preference. A clear benefit to overall survival was observed in patients who achieved remission following ven-aza initial therapy and went on to receive an allogeneic transplant, compared to patients that refused transplantation or were not considered candidates. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
